Financial Performance - For the three months ended March 31, 2023, the company recorded revenue of approximately RMB 142,544,000, a decrease of about RMB 50,823,000 compared to the same period last year[14]. - The profit attributable to shareholders for the same period was RMB 52,388,000, an increase of 56% from RMB 33,615,000 in the previous year[14]. - The basic earnings per share for the three months ended March 31, 2023, was RMB 0.0935, compared to RMB 0.0660 for the same period in 2022[30]. - Revenue for the first quarter of 2023 was RMB 142,544,000, a decrease of 26.3% compared to RMB 193,367,000 in the same period of 2022[61]. - Gross profit for the first quarter of 2023 was RMB 100,789,000, down 37.8% from RMB 161,864,000 year-over-year[61]. - Operating profit increased to RMB 67,224,000, compared to RMB 39,863,000 in the first quarter of 2022, representing a growth of 68.8%[61]. - Profit attributable to shareholders for the first quarter of 2023 was RMB 52,388,000, an increase of 55.8% from RMB 33,615,000 in the same quarter of 2022[61]. - Basic earnings per share for the first quarter of 2023 were 9.35 cents, compared to 6 cents in the first quarter of 2022, reflecting a 55.8% increase[61]. - Other income for the first quarter of 2023 was RMB 45,831,000, significantly up from RMB 5,701,000 in the same period last year[61]. Cost Management - The distribution and selling costs as a percentage of revenue decreased to 44.2% from 46.8% in the previous year, a reduction of 2.6%[15]. - Administrative expenses decreased from RMB 37,153,000 in the previous year to RMB 16,387,000 in the current year[15]. - Financial expenses decreased to RMB 26,000 from RMB 480,000 in the first quarter of 2022, indicating improved financial management[61]. Dividends - The company plans to distribute a special dividend of RMB 0.50 per share, totaling RMB 280,125,000, subject to shareholder approval[32]. - The board proposed a special dividend of RMB 0.50 per share, subject to shareholder approval at the upcoming extraordinary general meeting[34]. - The company declared a dividend of RMB 280,125,000 for the first quarter of 2023, compared to RMB 35,016,000 in the same period of 2022[61]. - The company did not recommend the payment of an interim dividend for the three months ended March 31, 2023[10]. Production and Operations - The company has officially commenced production in its small-volume injection workshop, increasing production capacity[37]. - The product catalog continues to expand, enhancing the company's R&D capabilities and market competitiveness[38]. - The company continues to operate in the manufacturing and distribution of traditional Chinese medicine and pharmaceutical products without any changes in business nature[62]. Financial Position - As of March 31, 2023, the company's cash and bank balances totaled RMB 978,742,000, up from RMB 834,176,000 in 2022[38]. - The unaudited net asset value of the group as of March 31, 2023, was approximately RMB 1,664,686,000, compared to RMB 1,487,364,000 in 2022[38]. - The capital debt ratio as of March 31, 2023, was 0.02%, a slight decrease from 0.03% on March 31, 2022[39]. - The company maintains a robust financial position, with no significant fluctuations in production and material costs reported[35]. Corporate Governance - The company has adopted a code of conduct for securities trading that meets or exceeds the standards set by GEM listing rules[55]. - The chairman, Zhang Hong, is also the CEO, a situation the board believes does not affect accountability or independent decision-making[57]. - The effective corporate income tax rate for the company remains at 15% for the three months ended March 31, 2023, consistent with the previous year[8]. - There were no potential diluted shares during the reporting period, hence no diluted earnings per share were presented[9].
吉林长龙药业(08049) - 2023 Q1 - 季度财报